Skip to nav Skip to content

Clinical Trial Search

293 Clinical Trials Found

Clinical Trial 22286

Disease Site: Leukemia, other
PI: Shah, Bijal

Clinical Trial 22485

Disease Site: Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 22557

Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 23059

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
Disease Site: Myeloid and Monocytic Leukemia
PI: Sallman, David

Clinical Trial 23161

Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 23399

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 21860

A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
Disease Site: Lymphoma
PI: Saeed, Hayder

Clinical Trial 21892

A Phase 2, Single-Arm, Open-Label Study using Itacitinib and Tafasitamab as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 20937

A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib In Refractory Advanced Thymic Carcinoma
Disease Site: Other Respiratory and Intrathoracic Organs
PI: Tanvetyanon, Tawee

Clinical Trial 21707

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)
Disease Site: Colon, Melanoma, skin, Rectum
PI: Sarnaik, Amod

Clinical Trial 21341

A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Disease Site: Eye and Orbit
PI: Tarhini, Ahmad